ArticleEpidemiology and infection2026
Time series analysis of new HIV diagnoses in France from 2012 to 2022.
Article in Epidemiology and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In France, HIV prevention measures including HIV testing, treatment, and uptake of pre-exposure prophylaxis (PrEP), have increased throughout the last decade. To analyse their impact, we performed a time series analysis of monthly HIV diagnoses reported via the national HIV surveillance database. In addition, we compared the timing of HIV promotional campaigns with monthly trends in HIV testing and PrEP initiation. From January 2012 to December 2022, new HIV diagnoses steadily decreased among men who have sex with men (MSM) born in France and heterosexuals born in France, whereas HIV diagnoses increased among MSM born abroad. HIV testing activity and PrEP use in France both steadily increased from 2014 to 2020, during which multiple campaigns targeting HIV testing and prevention occurred. The decline in HIV diagnoses among MSM born in France preceded the introduction of PrEP in 2016 and continued post-2016 without any acceleration in the rate of decline. Increased awareness of, access to and uptake of HIV prevention measures remain essential to progress towards HIV elimination in France, especially among MSM born abroad.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.